DC
CYCN icon

Davenport & Co’s Cyclerion Therapeutics CYCN Stock Holding History

Davenport & Co’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-650
Closed -$7K – 999
2022
Q2 		$7K Hold
650
– – ﹤0.01% 986
2022
Q1 		$14K Buy
650
+10
+2% +$241 ﹤0.01% 1057
2021
Q4 		$22K Buy
+640
New +$30.2K ﹤0.01% 1072
2021
Q2 		– Sell
-4,225
Closed -$236K – 950
2021
Q1 		$236K Buy
4,225
+3,324
+369% +$250K ﹤0.01% 718
2020
Q4 		$55K Buy
+901
New +$61.4K ﹤0.01% 774

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Davenport & Co's CYCN Position: Q3 2022 in Review

Davenport & Co sold out of Cyclerion Therapeutics (CYCN) in Q3 2022, closing a stake of 650 shares — an estimated $7K sold.

Davenport & Co first reported a position in CYCN in Q4 2020 and held it in 5 quarters. The position peaked at $236K in Q1 2021. 37 funds tracked by Wall St. Rank hold CYCN as of Q3 2022.

  • Davenport & Co reported no remaining Cyclerion Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Davenport & Co sold 650 Cyclerion Therapeutics shares in Q3 2022, an estimated $7K.
  • Davenport & Co first reported a position in Cyclerion Therapeutics in Q4 2020 and held it in 5 quarters.
  • Davenport & Co's Cyclerion Therapeutics position peaked at $236K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2022.

Based on Davenport & Co's 13F filing for Q3 2022, filed 11 Oct 2022.